Last updated: September 3, 2026
Glecaprevir/pibrentasvir, marketed by AbbVie as Mavyret and Maviret, is a fixed-dose, pan-genotypic hepatitis C virus treatment. The product remains commercially important because of its short treatment duration, broad genotype coverage, and use in patients with compensated liver disease. Its growth has continued after the initial direct-acting antiviral launch cycle, although pricing pressure, HCV screening gaps, declining prevalence, and future generic entry constrain long-term expansion.
AbbVie reported approximately $1.4 billion in Mavyret net revenue in 2023 and approximately $1.5 billion in 2024, based on annual-report product disclosures.[1,2] The product is expected to remain a billion-dollar franchise before patent-protected exclusivity begins to weaken in the early 2030s.
What is glecaprevir/pibrentasvir and how does it compete?
Glecaprevir/pibrentasvir combines two direct-acting antivirals:
- Glecaprevir, an NS3/4A protease inhibitor.
- Pibrentasvir, an NS5A replication-complex inhibitor.
Mavyret is administered once daily as three tablets taken with food. The standard treatment duration for many treatment-naive patients without cirrhosis is eight weeks. The regimen covers HCV genotypes 1 through 6 and is approved for adults and pediatric patients weighing at least 12 kilograms, subject to treatment-history and liver-disease restrictions.[3]
Its principal commercial advantages are:
- Eight-week treatment for many eligible patients.
- Pan-genotypic coverage without requiring genotype testing in many treatment settings.
- Activity in patients with chronic kidney disease, including severe renal impairment.
- A relatively simple regimen compared with older genotype-specific treatment strategies.
The main competing products are Gilead Sciences' Epclusa, Harvoni, and Vosevi. Epclusa is also pan-genotypic and has broad treatment utility. Harvoni remains relevant in selected genotype 1 and genotype 4 patients, while Vosevi is primarily used for retreatment after prior direct-acting antiviral failure.
How has Mavyret revenue changed over time?
Mavyret revenue expanded rapidly after U.S. launch and then stabilized at a high level. The product benefited from treatment initiation among previously untreated patients, broader payer access, and AbbVie's ability to compete aggressively on duration and net price.
AbbVie-reported Mavyret net revenue
| Fiscal year |
Approximate global net revenue |
Commercial interpretation |
| 2017 |
$159 million |
Partial-year launch |
| 2018 |
$862 million |
Rapid adoption and formulary expansion |
| 2019 |
$1.03 billion |
First full billion-dollar year |
| 2020 |
Approximately $1.0 billion |
Pandemic-related treatment disruption |
| 2021 |
Approximately $1.1 billion |
Recovery in treatment starts |
| 2022 |
Approximately $1.3 billion |
Continued U.S. demand and international contribution |
| 2023 |
Approximately $1.4 billion |
Stable mature-franchise growth |
| 2024 |
Approximately $1.5 billion |
Continued revenue resilience before patent expiry |
The historical figures are rounded from AbbVie's annual reports and product-revenue tables.[1,2,4-7] Mavyret's revenue trajectory differs from many conventional chronic medicines. HCV treatment is curative, so each treated patient leaves the addressable pool. Revenue therefore depends on identifying untreated or reinfected patients, expanding screening, reaching underserved populations, and maintaining payer access.
The 2020 decline in treatment activity reflected reduced health-care utilization during the COVID-19 pandemic. Subsequent growth came from the resumption of testing and treatment, continued use among patients with barriers to care, and international programs.
What drives the Mavyret market?
The market is driven more by diagnosis and treatment access than by traditional chronic-disease prevalence.
HCV elimination programs
The World Health Organization has set a target of eliminating viral hepatitis as a public-health threat by 2030. National programs are expanding screening among people who inject drugs, incarcerated populations, migrants, and patients with prior transfusion or other exposure risks.[8]
The commercial opportunity depends on whether health systems can convert screening into treatment. Barriers include:
- Low diagnosis rates.
- Fragmented care.
- Limited specialist availability.
- Reinfection among high-risk populations.
- Prior authorization requirements.
- Treatment interruption.
- Weak linkage between testing and dispensing.
Expanded screening can offset the natural decline in untreated HCV prevalence. In the United States, public-health initiatives aimed at low-income and high-risk populations are more important to future volume than traditional physician prescribing growth.
Short-course therapy and simplified care
Mavyret's eight-week course can reduce the operational burden of treatment. This supports use in primary-care, correctional, community-health, and telehealth settings. The product's pan-genotypic profile also reduces dependence on genotype-specific prescribing.
Payer economics
AbbVie launched Mavyret with a list price of $26,400 for an eight-week course, materially below the list price of some competing HCV regimens at the time.[9] Actual net pricing is lower because of Medicaid rebates, commercial rebates, government discounts, patient-assistance programs, and institutional contracting.
This pricing strategy helped AbbVie secure formulary access but limits the relationship between prescription volume and revenue. Large public-sector customers and state Medicaid programs can exert substantial price pressure through preferred-product arrangements and outcomes-based procurement.
How does Mavyret compare with Epclusa and other HCV drugs?
| Product |
Company |
Core components |
Principal position |
| Mavyret |
AbbVie |
Glecaprevir/pibrentasvir |
Eight-week, pan-genotypic therapy for many patients |
| Epclusa |
Gilead |
Sofosbuvir/velpatasvir |
Broad pan-genotypic treatment and major competitor |
| Vosevi |
Gilead |
Sofosbuvir/velpatasvir/voxilaprevir |
Retreatment after prior DAA failure |
| Harvoni |
Gilead |
Sofosbuvir/ledipasvir |
Earlier-generation genotype-focused product |
| Zepatier |
Merck |
Elbasvir/grazoprevir |
Narrower genotype and resistance profile |
Mavyret's strongest competitive position is in treatment-naive patients who qualify for an eight-week regimen. Epclusa retains strength where clinicians prefer a sofosbuvir-based regimen, where genotype-specific clinical history favors it, or where treatment protocols are established around Gilead products.
The competitive market is mature. Differentiation increasingly depends on contracting, distribution, treatment simplification, renal utility, public-health access, and patient support rather than large efficacy differences.
When does Mavyret lose exclusivity?
Mavyret's key U.S. patent protection is generally associated with the early 2030s, with composition and formulation protection reported to extend to approximately 2032, subject to patent-specific terms, pediatric extension, terminal disclaimers, and litigation outcomes.[1,10]
U.S. exclusivity timeline
| Event |
Date or period |
| FDA approval of Mavyret |
August 2017 |
| Pediatric expansion |
2019 and later label updates |
| Core U.S. patent protection |
Approximately 2032 |
| Likely generic preparation period |
Late 2020s to early 2030s |
| Earliest meaningful generic risk |
Approximately 2032, subject to challenges and settlements |
FDA approval was granted on August 3, 2017.[3] The product does not face biosimilar risk because glecaprevir/pibrentasvir is a small-molecule chemical drug, not a biologic. The relevant threat is abbreviated new drug application, or ANDA, competition.
Exact generic entry timing depends on the Orange Book-listed patents, any Paragraph IV certifications, patent litigation, six-month pediatric exclusivity, and settlement agreements. Patent expiration is therefore more important than the remaining regulatory exclusivity period.
What patents protect glecaprevir/pibrentasvir?
Protection is based on a layered estate rather than one patent. The portfolio includes patents and patent families covering:
- Glecaprevir chemical compounds.
- Pibrentasvir chemical compounds.
- Specific stereochemical and salt forms.
- Pharmaceutical compositions.
- The fixed-dose combination.
- Combination treatment of HCV.
- Treatment duration and patient populations.
- Manufacturing and intermediate processes.
Enanta Pharmaceuticals discovered glecaprevir and collaborated with AbbVie on HCV development. Enanta has stated that its HCV collaboration with AbbVie provides royalties on Mavyret sales, while AbbVie commercializes the product.[11]
Patent estate strength
The estate is commercially strong for four reasons:
- It protects two active ingredients rather than one.
- It includes compound-level protection with greater litigation value than a narrow method-of-use claim.
- The fixed-dose combination creates additional formulation and composition barriers.
- The product is supported by a large clinical and regulatory record that can make a full substitution strategy more complex.
The estate is less durable after core compound patents expire because an ANDA applicant can seek approval based on bioequivalence without reproducing every proprietary manufacturing process. Process patents may raise supply-chain and infringement risks but are usually less effective than valid composition patents at preventing generic launch.
What is the Orange Book status of Mavyret?
Mavyret is an FDA-approved small-molecule product with Orange Book-listed patent protection. The relevant listings can include patents covering the active ingredients, combination product, and approved use.[10]
An ANDA applicant must address listed patents through one of four certifications:
- Paragraph I: No patent information is listed.
- Paragraph II: The patent has expired.
- Paragraph III: The applicant will wait until patent expiration.
- Paragraph IV: The patent is invalid, unenforceable, or not infringed.
A Paragraph IV filing would require AbbVie or another patent owner to bring infringement litigation within 45 days to trigger an automatic FDA approval stay of up to 30 months, subject to statutory exceptions and court developments.[12]
Publicly available commercial disclosures do not establish a broad, settled generic-launch schedule for Mavyret. The main risk window remains tied to the early-2030s patent horizon rather than near-term substitution.
Which companies are challenging Mavyret?
The principal future challengers are likely to be generic manufacturers with experience in complex antiviral products, including large Indian and global generic companies. The commercial field could include companies such as Teva Pharmaceutical Industries, Viatris, Sandoz, Dr. Reddy's Laboratories, Cipla, Sun Pharmaceutical, and other ANDA filers.
A definitive list of Mavyret Paragraph IV challengers requires current FDA Orange Book records, ANDA litigation dockets, and company disclosures. Patent challenges may remain confidential or may not produce litigation until an ANDA notice is served.
The most likely challenge structure is a product-by-product attack on listed patents, with different filers targeting compound, combination, and method-of-use claims. A successful Paragraph IV challenge could accelerate entry before the nominal 2032 expiry date. A settlement could permit a negotiated launch date, potentially with an authorized generic arrangement or other commercial terms.
What generic entry risks exist for Mavyret?
Generic entry would likely produce a sharp reduction in net price. The effect on volume would be smaller than in chronic maintenance drugs because the treated course is short and the patient population is finite.
Generic launch scenarios
| Scenario |
Timing |
Financial effect |
| Patent-protected launch |
Before 2032 only if challenge succeeds |
Rapid price erosion and loss of branded share |
| Negotiated early entry |
Before or near 2032 |
Gradual erosion depending on settlement terms |
| At-risk launch |
Before final patent resolution |
High litigation exposure for the generic and potential damages |
| At-expiry launch |
Around 2032 or later |
Rapid payer substitution and lower branded revenue |
AbbVie may retain some volume through Medicaid contracts, patient-support programs, brand trust, and supply reliability. Those advantages are unlikely to preserve current revenue levels once multiple therapeutically equivalent generics receive approval.
Enanta's royalty revenue would also face pressure because its economics are linked to Mavyret sales rather than an independent commercial product. AbbVie's risk is larger in absolute dollars because it records the product's sales and bears commercial infrastructure costs.
What litigation and settlement issues affect Mavyret?
The principal legal issues are likely to involve:
- Validity of compound patents.
- Written-description and enablement challenges.
- Obviousness of the combination or specific compounds.
- Infringement of composition and method-of-use claims.
- Patent-term adjustment and pediatric exclusivity.
- The enforceability of formulation and manufacturing patents.
- The terms of any Paragraph IV settlement.
HCV products have generated substantial patent litigation across the industry, particularly involving Gilead's sofosbuvir portfolio and licensing arrangements. Mavyret's legal profile is distinct because the commercial product contains two AbbVie/Enanta-origin active ingredients and competes against other pan-genotypic regimens.
No settlement should be assumed without a disclosed agreement or court record. A generic settlement could materially alter the nominal patent-expiry analysis by allowing an agreed launch date before the last listed patent expires.
How strong is the financial outlook for glecaprevir/pibrentasvir?
The near-term outlook is stable to positive, but the long-term outlook is defined by a patent cliff.
Near-term, 2025-2028
Revenue should remain supported by:
- Continued HCV diagnosis and treatment.
- International elimination programs.
- Use in patients with renal impairment.
- Eight-week treatment convenience.
- Established payer and distributor relationships.
- Limited near-term generic substitution.
Growth is likely to be moderate rather than launch-like. Market expansion depends on finding untreated patients, not on repeat chronic prescriptions.
Medium term, 2028-2031
Competitive pressure should increase as payers prepare for patent expiry and generic manufacturers begin regulatory filings. AbbVie may respond with higher rebates, contracting, inventory management, and public-health partnerships. Revenue could remain resilient if screening expands, but net price is likely to weaken before formal generic entry.
Long term, 2032 onward
A material decline is likely once multiple generics enter. The pace will depend on the number of approved manufacturers, the outcome of patent litigation, state Medicaid policies, and whether AbbVie launches or authorizes a generic version.
The product's finite-treatment model means that generic entry can compress both price and branded prescription share quickly. Mavyret's revenue exposure is meaningful for AbbVie but small relative to its immunology and oncology franchises. In 2024, Mavyret represented roughly 1% of AbbVie's total revenue based on reported corporate sales and rounded product revenue.[2]
What manufacturing and intellectual-property barriers protect the product?
Manufacturing barriers are meaningful but secondary to compound patents. Mavyret requires control of complex active pharmaceutical ingredients, stereochemistry, impurities, solid-state properties, and a reproducible fixed-dose tablet process.
Potential generic barriers include:
- Synthesis of glecaprevir and pibrentasvir at commercial scale.
- Control of impurity profiles.
- Demonstration of bioequivalence for a three-tablet regimen.
- Access to qualified active-ingredient suppliers.
- Patent risk involving intermediates and process claims.
- Regulatory requirements for combination-product consistency.
These barriers can delay entry or reduce the number of initial competitors. They are unlikely to prevent competition after strong composition patents expire because major generic manufacturers can develop alternative processes.
What is the FDA regulatory status of Mavyret?
Mavyret is FDA-approved for treatment of chronic HCV infection in adults and pediatric patients meeting the labeled age and weight criteria. The FDA label includes genotype-specific restrictions, contraindications involving severe hepatic impairment, and drug-interaction warnings.[3]
The product is not a biologic and does not use the Biologics Price Competition and Innovation Act pathway. Generic competitors would file ANDAs under the Hatch-Waxman framework.
Key Takeaways
- Glecaprevir/pibrentasvir is AbbVie's Mavyret, a pan-genotypic, fixed-dose HCV regimen.
- AbbVie revenue has grown from $159 million in 2017 to roughly $1.5 billion in 2024.
- The franchise benefits from eight-week therapy, broad genotype coverage, renal utility, and HCV-elimination programs.
- The market is mature and depends heavily on diagnosis, treatment access, public-sector contracting, and net-price management.
- The main competitor is Gilead's Epclusa, with Vosevi and Harvoni occupying narrower or retreatment positions.
- Mavyret has no biosimilar risk. Its key future threat is ANDA-based generic competition.
- Core U.S. patent protection is generally associated with the early 2030s, approximately 2032, subject to patent-specific adjustments and litigation.
- Paragraph IV challenges could accelerate entry, but a confirmed broad generic-launch schedule is not established in the cited public disclosures.
- Generic entry would likely cause rapid net-price erosion and a steep decline in branded revenue.
- Mavyret is strategically important to AbbVie but represents a small share of total corporate revenue.
FAQs
How long is the standard Mavyret treatment course?
Many treatment-naive patients without cirrhosis receive an eight-week course. Treatment duration varies according to genotype, prior treatment, cirrhosis status, and other label requirements.
Is glecaprevir/pibrentasvir interchangeable with Epclusa?
The products are not automatically interchangeable. Both are pan-genotypic, but treatment selection depends on renal function, liver status, prior therapy, drug interactions, genotype-related considerations, payer rules, and prescriber judgment.
Does Mavyret have pediatric exclusivity?
FDA pediatric exclusivity can extend qualifying patent or regulatory protection by six months. The commercial impact depends on which listed patent is eligible and the applicable expiration calculation.[12]
Who owns the active-ingredient intellectual property for Mavyret?
AbbVie commercializes Mavyret under its collaboration with Enanta Pharmaceuticals. Enanta discovered glecaprevir and receives royalties and other economic benefits under the collaboration arrangements.[11]
Could a generic Mavyret launch before 2032?
Yes, but only if a challenger successfully invalidates or avoids relevant patents, reaches a settlement allowing earlier entry, or launches at risk while litigation remains unresolved. A nominal patent expiry date does not by itself determine the actual market-entry date.
References
- AbbVie Inc. (2024). 2023 annual report.
- AbbVie Inc. (2025). 2024 annual report.
- U.S. Food and Drug Administration. (2024). Mavyret prescribing information.
- AbbVie Inc. (2019). 2018 annual report.
- AbbVie Inc. (2020). 2019 annual report.
- AbbVie Inc. (2021). 2020 annual report.
- AbbVie Inc. (2022). 2021 annual report.
- World Health Organization. (2024). Global hepatitis report 2024.
- AbbVie Inc. (2017). AbbVie announces FDA approval of Mavyret for chronic hepatitis C.
- U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations, Orange Book.
- Enanta Pharmaceuticals, Inc. (2024). 2023 annual report.
- U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355 and 35 U.S.C. § 156.
